Correlation of sera TNF-α with percentage of bone marrow plasma cells, LDH, β2-microglobulin, and clinical stage in multiple myeloma
- 117 Downloads
Tumor necrosis factor-α (TNF-α) is important for function, differentiation, and transformation of B-lymphocytes in multiple myeloma (MM) but can also induce apoptosis of myeloma cells. Based on this opposite effect, it is very crucial to analyze the correlation of the serum level of TNF-α with clinical parameters of the patients. In this article, we analyzed 18 MM patients, 48% male and 52% female, with a mean age of 52 yr (range: 35–81 yr), clinical stage I in 21.4%, stage II in 26.4%, and stage III in 52.2% of patients. Patients with advanced clinical stage, presence of osteolysis, and elevated lactate dehydrogenase (LDH) had a significant difference (Mann-Whitney U-test, p<0.05) in the serum level of TNF-α in comparison with those in the early stage, without osteolysis, and normal LDH. The correlation of individual values of TNF-α with the percentage of plasma cells in the bone marrow, LDH, β2-microglobulin, fibrinogen, and sedimentation rate was significant (p<0.05). However, we have not found a significant correlation between TNF-α and concentration of hemoglobin, the number of white blood cells or platelets (p>0.05). We concluded that our data indicate determination of TNF-α as a good parameter for estimation of tumor mass presence, among individual patients with MM, and may by used for monitoring during application of different therapy protocols.
Key WordsMultiple myeloma TNF-α lactate dehydrogenase β2-microglobulin clinical stage
Unable to display preview. Download preview PDF.
- 3.Greipp, P.R. and Kyle, R.A. (1996). Staging, kinetics, and prognosis of multiple myeloma, in: Neoplastic Disease of the Blood (Wiernik, P., Canelos, G., Ducher, J. and Kyle, R., (eds), pp537–559, Churchill Livingstone, New York.Google Scholar
- 5.Hatzoglou, A., et al. (2000). TNF receptor family member BCMA (B cell maturation) associated with TNF receptor-associated factor (TRAF) TRAF 2, and TRAF3, and activates NF-kappa B, elk-1, c-Jun N terminal kinase, and p38 mitogen activated protein kinase. J. Immunol. 165, 1322–1330.PubMedGoogle Scholar
- 8.Hata, M., Matsuzaki, K. and Tkatsuki, K. (1990). Autocrine growth by two cytokines, interleukin 6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A. Acta Hematol. 83, 133–136.Google Scholar
- 11.Usnarska-Zubkiewicz, L. (1998). Level of interleukin-6 (IL-6), soluble interleukin-6 receptors (sIL-6R) and tumor necrosis factor alpha (TNF-alpha) in untreated and progressing multiple myeloma. Pol. Arch. Med. Wewn. 1, 30–37.Google Scholar
- 12.Desser, L., Sakalova, A., Zavdova, E., Holomanova, D. and Mohr, T. (1997). Concentration of soluble tumor necrosis factor receptor, β2-microglobulin, IL-6, and TNF in serum of multiple myeloma patients after chemotherapy and after combined enzyme-chemotherapy. Int. J. Immunother. 13, 121–130.Google Scholar
- 16.Jourdan, M., et al. (1999). Tumor necrosis factor is survival and proliferation factor for human myeloma cells. Eur. Cytok. Network 10, 65–70.Google Scholar
- 18.Rodon, P., et al. (2001). Multiple myeloma in elderly patients: presenting and features and outcome. Br. J. Haematol. 66, 11–17.Google Scholar